(+)-VINCRISTINE
Adult Diffuse Astrocytoma
Novartis PharmaceuticalsSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Adult Diffuse Astrocytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Tas-102 National Cancer Institute (NCI) | Phase 2 | B |
su011248 National Cancer Institute (NCI) | Phase 2 | B |
Temsirolimus National Cancer Institute (NCI) | Phase 1/2 | CCC |
Panobinostat National Cancer Institute (NCI) | Phase 1/2 | CCC |
View all 20 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →